Method for treating the cases of non-operable cardiologic patients

FIELD: medicine.

SUBSTANCE: method involves using mononuclear autologic marrow fraction containing 6-9x104 mesenchyma cells per 1 ml or autologic mesenchyma trunk cells. The cells are separated from brain bioptate in the amount of 106 cells/kg of patient body mass. The preparations are intracoronarily introduced in fractions at a rate of 3-5 ml/min into the right coronary artery. The introduction is also carried out in intra-arterial mode in jets or in drops.

EFFECT: higher survival rate and life quality of cardiologic patients.

1 dwg

 

The invention relates to medicine, more specifically to cardiology and cardiovascular surgery, and may find application in the treatment of cardiac patients.

The proposed method for the treatment of inoperable patients with ischemic heart disease and idiopathic dilated cardiomyopathy, who belong to one of the most difficult groups of cardiac patients and for which there is currently no specific treatment.

Coronary heart disease (CHD) is one of the major causes of disability and death. Treatment of disease is carried out mainly through drug therapy. Operative (surgical) treatment of coronary heart disease runs in the event of failure of medical therapy or in cases where the nature of the lesion of the coronary arteries determines a high risk of cardiac death (Recommendations by the American Heart Association and American College of Cardiology “Coronary bypass surgery” JACC, Vol.34, No. 4, October 1999:1262-1347). Inoperable patients are patients of coronary heart disease in whom the risk of surgery outweighs the expected benefit of surgical treatment in the form of elimination of symptoms that limit activity. These patients constitute the most severe category CHD patients as medical cured the e already inefficient and the severity of the condition or the nature of the lesion of vessels of the heart makes it almost impossible for surgical treatment. However, surgical treatment remains in this category of patients the only way to save lives.

Idiopathic dilated cardiomyopathy (IDCMP) - incurable genetically determined myocardial damage, inherited in an autosomal dominant or autosomal recessive principle (Towbin J, Bowie S, Ortiz-Lopez R, Wang Q. Genetic basis of dilated cardiomyopathy. Cardiomyopathies 1999; 56-65.). IDCMP is one of the most frequent reasons for the development of severe heart failure not amenable to medical therapy. Failures in drug therapy IDCMP require solving the issue of heart transplant (Olson T, Michels V., et al. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure // Sciense 1998; 280) or implantation of mechanical devices (Gronda F., Vitali E. Left ventricle assist systems: a possible alternative to heart transplantation for heart failure patients? Patient selection, techniques and benefit. Eur j Heart Failure, Dec 1999; 1: 320-5.)

Specific treatment IDCMP currently there.

A known method of surgical treatment of patients with coronary artery disease, which consists in restoring blood flow and metabolism of the affected areas of the myocardium by imposing coronary artery anastomosis or perform endovascular angioplasty and testirovanie. However, the majority of patients due to the severity of their condition and this surgical the intervention is not feasible.

There is a method of medical treatment IDCMP, involving the use of inhibitors of angiotensin-converting enzyme (ACE inhibitors), diuretics drugs, drugs with positive inotropic action, etc. However, this method is symptomatic, and ineffective.

Thus, the only specific treatment for unresectable cardiac patients as CHD and IDCMP is a heart transplant is not available to the vast majority of patients, since the number of such patients exceeds the number of donors.

Closest to the proposed medication is the treatment of this category of patients (Treatment of heart failure. Recommendations of the working group for the study of heart failure of the European society of Cardiology. Eng. the honey. Journe. App. 1999.), taken as a prototype.

Because medical therapy, the purpose of which is to reduce clinical manifestations of heart failure - complications of the underlying disease, not aimed at restoring the function of the heart muscle, the quality of life of these patients is poor and the mortality remains high (more than 50% of patients die within the first year when severe heart failure). The specific honey is comentsno therapy for this category of patients is not currently exist.

The technical result of the present invention is to improve patient survival and improve their quality of life.

This result is achieved by the fact that in the treatment of inoperable patients with coronary artery disease and IDCMP use of autologous mononuclear fraction of bone marrow containing 6-9×104mesenchymal cells in 1 ml or autologous mesenchymal stem cells (AMSC) in an amount of 106cells/kg of body weight of the patient, which is injected intracoronary fractional volume up to 50 ml with a maximum speed of 5-10 ml/min in the left and 30 ml fractionally with a maximum speed of 3-5 ml/min in the right coronary artery, and if the patient's condition does not allow the introduction of intracoronary, perform intravenous drip or bolus intra-arterial administration.

Earlier experimental and clinical studies have shown (Zhang S et/al. Transplantation of bone marrow cells upregulated vascular endothelial growth factor and its receptor and improved ischemic myocardial function. Beijing Da Xue Xue Bao. 2003; 35(4):429-433), that the application of the mononuclear fraction of bone marrow or stem cell cultures in acute tissue damage accompanied by activation recovery (repair) processes functioning tissue and reduction in the formation of substitution scar (fibrous) tissue (Assmus Century. Et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002; 106(24): 009-3017). However, the reverse development is already formed fibrous tissue of the heart and the acquisition of metabolic traits characteristic of the functioning of the myocardium is impossible (Kipshidze n, Serruys P. Handbook of Cardiovascular Cell Transplantation // Martin Dunits, UK, 2004:P425). This is because the most likely stimulus for the differentiation of stem cells into specific tissue products are acute loss of the corresponding tissue.

It is known the use of stem cells in the bone marrow (as the culture of hematopoietic, mesenchymal cells, and in the composition of the mononuclear mist) during operations on the heart, treatment of acute myocardial infarction, aimed at the activation of regenerative processes functioning tissue and reduce the formation of fibrous tissue in the acute coronary insufficiency (Stamm With et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 2003; 361; 9351: 45-46; Tse H-F et al. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 2003; 361; 9351: 47-49; Assmus et al In. Transplantation of progenitor cells and regeneration enchancment in acute myocardial infarction. Circulation Circulation 2002; 106: 3009-3017; Strauer BE et al. Repair ofinfarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002; 106). However, the reverse development is already formed fibrous tissue of the heart and the acquisition of metabolic traits characteristic of the functioning of the myocardium, as said above, is impossible. Fibrous is fabric - not functional, it is not able to reduce, and a low (relative to muscle tissue) consumption of glucose. In positron emission tomography (PET) heart using Tordesillas, labeled with radioactive fluorine [18F], fibrous tissue is detected as a focus of reduced metabolism Tordesillas.

The use of stem cells in patients with no acute focal changes seemed meaningless because these patients there are no incentives for the differentiation of stem cells into specific tissue (no acute necrosis of tissue). And if attempts were made to use stem cells in patients with chronic ischemic heart disease, the introduction of intracoronary cells was accompanied by a modeling ischemia by inflating the balloon in the lumen of the coronary vessel, and intramyocardial the background was always accompanied operating injury.

Mononuclear suspension obtained by sedimentation punctate bone marrow by density gradient with hexaethyltriamido and centrifugation supernatant.

ASK is the fraction of highly purified native mesenchymal stem cells. To obtain AMSC need to fence in a patient 20-35 ml bone marrow (the procedure is performed under short-term anesthesia and continues the I within 10-15 minutes). Further from the bone marrow are highlighted in ASK that tipiloura and are grown in a special medium. After 10-12 days from the start of culturing, the number of AMSC reaches 80-100 million, which is ten times higher than the content in the bone marrow.

We have tried to introduce mesenchymal stem cells to the patient, which in the operative (surgical) treatment was denied because of the severity of vascular lesions of the heart, and the provisions of drug therapy were already exhausted. As shown by the results of this study, the patient's condition significantly improved exercise tolerance increased, which indicated the improvement of cardiac function. The results of the ultrasound and PET studies have confirmed positive changes in the heart. This fact and the basis of the present invention.

The essence of the method is illustrated by examples.

Example 1. Patient M born in 1948, and a/b No. 3323 was admitted to the hospital 16.12.2003 with a diagnosis of CHD. Angina III-IV voltage and peace. Atherosclerosis and myocardial infarction (myocardial infarction in 1999, 2003).

Ventricular fibrillation 14.03.2003. NC - III (NYHA)

Upon receipt worried about the pain with minimal exertion, night pain at rest shortness of breath with minimal physical activity.

When echocardiographies the MD study areas of akinesia in the anterior-apical segment and hypokinesia in the rear-lower segments of the left ventricle. Contractility of the left ventricle is reduced (EF=44%).

Performed coronary angiography No. 974 from 18.12. 2003:

Local anesthesia Sol. Novocaini 0.25%-30.0. Puncture and catheterization a.femoralis dextra. Selective coronary angiography LCA and RCA (contrast “Ultravist”).

Type of blood: mixed

Selective coronary angiography LCA:

The trunk of LCA: without stenotic changes. The left descending artery (LAD): Diffuse changed. Occlusion after discharge major diagonal branch. Collateral filling no. Envelope artery (LCX): Diffuse changed from the mouth throughout with a maximum stenosis of 80% in the proximal segment. The right coronary artery (RCA). Occlusion of the proximal segment. Retrograde filling of the LCA system.

Given the nature of the coronary lesion and the patient's condition, surgical revascularization was denied.

The patient after signing the informed consent produced by the puncture of the iliac crest, received ~ 180 ml of bone marrow from which the selected mononuclear fraction containing 6.0×104mesenchymal cells in 1 ml, and injected intracoronary fractional volume of 40 ml at a rate of 10 ml/min in the left and 30 ml of fractional speeds of 3-5 ml/min in the right crowns the RNA artery. When you try to increase the speed of the left coronary artery is almost instant increase of ischemic changes on EKG (pain was not).

Introduction mononuclear mist patient satisfactorily and 22.12.2003 was discharged from the hospital.

With repeated follow-up at 3 months (drawing B) after injection of mononuclear mist - the disappearance of pain alone. In re PET study, normalization of metabolism in the scar area after myocardial infarction (in segments with baseline hypometabolism of glucose (drawing) there is an increase in capture of the radiopharmaceutical at 46-127%). Load exercise test revealed a significant increase in tolerance to physical load (110 watts). Cardiac contractile force increased during the observation period from 44% to 53%, including regional contractility in areas with original Hypo-akinesia.

Subsequent dynamic observation in April 2004 and July 2004 confirmed the positive effect of the treatment.

Example 2. Patient B. 1950 birth, and/b 949, was admitted to the hospital 26.03.2004. the invalid of I group. The diagnosis of CHD. Angina III-IV functional class and rest. Atherosclerosis and myocardial infarction (re-myocardial infarction in 2001, 2002). Chronic heart is Naya failure Art. IV

Admission: koronarograficheskie study (clinic, military medical Academy, Kirov, small - diameter coronary vessels, tresolution defeat). Consulted in the cardiac branches of the Kirov military medical Academy, research Institute of cardiology of Russian Federation Ministry of health. Surgical revascularization is denied. Ultrasonic examination of the presence of pericardial effusion, the fraction of exile 22%, mitral and tricuspid insufficiency. Objectively a serious condition, heart rate 120 in 1 min, NPV 26 in 1 min. Indurativnyy edema of the lower extremities up to the level of the lower third of the thigh, refractory to ongoing diuretic therapy. Cachexia.

Daily attacks of cardiac asthma. Given the bad condition of the patient and high risk of death, it was decided to intravenous him ASK.

Analogously to example No. 1 was punctured bone marrow derived sampling, from which were selected AMSC, then typed and grown in a special medium. After 10-12 days from the start of culturing, the number of AMSC reached 70 million AMSC were introduced intravenously. The insertion procedure was carried to the sick satisfactory and the patient was discharged from the hospital. Through 1 month after the introduction of the gradual improvement of health, reduction of signs of heart failure.

3 months after the introduction of the culture of mesenchymal cells distinct wedge the economic improvement - the disappearance of refractoriness to ongoing diuretic therapy. Reduction of swelling of the lower extremities to pastoznost legs. The disappearance of the attacks of cardiac asthma. The possibility to sleep at night. Increases in motor activity. Fraction of exile - 28%. In re PET study distinct improvement of metabolism in the scar area after suffering a myocardial infarction (in segments with initial glucose hypometabolism observed increase in the capture of the radiopharmaceutical). Subsequent dynamic observation in July 2004 confirmed confirmed positive effect of the treatment.

Example 3. Patient M., born in 1956, the patient with severe right-left ventricular failure (Chronic heart failure (CHF) IV functional class)due to idiopathic DC.

From the anamnesis: About the disease learned after the first clinical manifestations of heart failure and follow-up examinations. Simpaticheskaja therapy ineffective.

The growth of liver failure.

Admission: State of moderate severity. Shortness of breath when talking. HR - 110 in 1 min Interesest sclera. Edema of the lower extremities. Cardiac cirrhosis. Contractility of the heart is sharply reduced (EF=32%). Mitral, tricuspid regurgitation.

PA is Ianto after signing the informed consent produced by the puncture of the iliac crest, received ~180 ml of bone marrow from which the selected mononuclear fraction containing 9.0×104mesenchymal cells in 1 ml Estimated volume survey included coronary angiography and intracoronary introduction mononuclear mist.

However, for technical reason, intracoronary introduction mononuclear suspension failed, the suspension was introduced intraarterially jet (descending aorta).

3 days after injection of mononuclear mist patient was discharged.

After 3 months at follow-up - change in the functional class of CHF to II-III (article). The increase in contractility to 39%. In re PET study: reducing the size of the area of hypometabolism of glucose in the apical segment of the lower wall of the left ventricle, the disappearance of the area of hypometabolism in the middle segment of the interventricular septum.

Subsequent dynamic observation over 6 months, 9 months. and 1 year confirmed achieved clinical effect.

Example 4. Patient B. 54 years, patients with idiopathic DC.

Chronic heart failure IV functional class (NYHA classification).

Admission: State of moderate severity. Sleep half-sitting. Sinus tachycardia with a heart rate of 96 beats per 1 minute of Hepatomegaly. Edema of the lower extremities. Contractile ability is ü heart dramatically reduced (EF=37%). Mitral, tricuspid regurgitation.

Analogously to example No. 1 was punctured bone marrow derived sampling, from which were selected AMSC, then typed and grown in a special medium. Two weeks from the beginning of cultivation, the number of AMSC reached 80 million AMSC were introduced intravenously. The insertion procedure was carried to the sick satisfactory and the patient was discharged from the hospital.

3 months after intravenous culture of mesenchymal stem cells - the change in the functional class of CHF to II-III (article). When re-PET study in segments with initial glucose hypometabolism observed increase in the capture of the radiopharmaceutical. Cardiac contractile force increased to 45%.

Follow-up for 9 months achieved confirmed the positive effect of the treatment.

To date, the proposed method of treatment more than 30 unresectable patients who injected mesenchymal stem cells in mononuclear suspension or tissue culture. None of the patients to date is not lost. The proposed method is compared with the prototype has a number of advantages:

1. Provides a higher survival rate in the most severe group of cardiac patients. When medical therapy, as you specified is e, more than 50% of patients die within the first year when severe heart failure. Transplantation of hearts is not available for the vast majority of patients, since the number of such patients exceeds the number of donors.

2. Quality of life invalidizirovannyh patients who were treated in the above manner, was significantly higher. All patients increased exercise tolerance. This made it possible not only to maintain themselves in everyday life, but also to increase the level of social adaptation (easy work).

The method developed in the clinic cnerry MZ the Russian Federation (St. Petersburg) together with the staff of the city hospital # 2, St.-Petersburg state medical University named after academician I.P. Pavlov and was clinically tested in 30 patients with a positive result.

A method for the treatment of unresectable cardiac patients by injecting the patient a therapeutic agent, characterized in that as a remedy using autologous mononuclear fraction of bone marrow containing 6-9×104mesenchymal cells in 1 ml of autologous mesenchymal stem cells in an amount of 106cells/kg of body weight of the patient, which is injected or intracoronary fractional volume up to 50 ml with a maximum speed of 5-10 is l/min in the left and 30 ml fractionally with a maximum speed of 3-5 ml/min in the right coronary artery, or intraarterially inkjet, or intravenous drip.



 

Same patents:

FIELD: new 2,4,6-trimethyl-3-oxypyridine nitrosuccinate and method for production thereof.

SUBSTANCE: claimed compound is useful in medicine as future antiishemic agent with vasodilatation effect and has potent protective action in barotraumatic damages and ballistic wounds due to inhibition of secondary necrosis creation and progress. Compound of present invention is obtained by nitration of malic acid with mixture of sulfuric and nitric acids, separation of nitrohydroxymalic acid and treatment thereof with 2,4,6-trimethyl-3-oxypyridine in alcohol media with subsequent isolation of target product.

EFFECT: new antiishemic agent.

2 cl, 1 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with phospholipid complexes of proanthocyanidine A2 and pharmaceutical compositions upon their basis as antiatherosclerotic agents, those for preventing and treating myocardial and cerebral infarction. Phospholipids of the above-mentioned complex should be preferably chosen out of lecithins, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl serine. The innovation provides the preparation to treat the above-mentioned diseases due to decreasing the quantity and burden of atheromatous plaque, decreased obstruction of carotid arteries and decreased thickness of vascular walls.

EFFECT: higher efficiency of prophylaxis and therapy.

9 cl, 11 dwg, 6 ex, 2 tbl

FIELD: organic chemistry, biochemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new aminobenzophenones of the formula (I):

or their pharmaceutically acceptable salts. These compounds elicit properties of inhibitors of cytokines secretion, in particular, 1β-interleukin (IL-1β) and tumor necrosis α-factor (TNF-α) and to secretion of polymorphonuclear superoxide that are useful for treatment of inflammatory diseases, for example, skin diseases, such as psoriasis, atopic dermatitis. In the formula (I) R1 is taken among the group consisting of halogen atom, hydroxy-, mercapto-group, trifluoromethyl, amino-group, (C1-C3)-alkyl, (C2-C3)-olefinic group, (C1-C3)-alkoxy-, (C1-C3)-alkylthio-, (C1-C6)-alkylamino-group, (C1-C3)-alkoxycarbonyl, cyano-group, carbamoyl, phenyl or nitro-group under condition that when R1 means a single substitute then it at ortho-position, and when R1 means more one substitute then at least one substitute of R1 is at ortho-position; R2 means one substitute at ortho-position being indicated substitute is taken among the group consisting of (C1-C3)-alkyl, (C1-C3)-alkoxy-group; R3 means hydrogen, halogen atom, hydroxy-, mercapto-group, trifluoromethyl, amino-group, (C1-C3)-alkyl, (C2-C3)-olefinic group, (C1-C3)-alkoxy-, (C1-C3)-alkylthio-, (C1-C6)-alkylamino-group, (C1-C3)-alkoxycarbonyl, phenyl, cyano-, carboxy-group or carbamoyl; R4 means hydrogen atom or (C1-C3)-alkyl; Q means a bond or -SO2-; Y means (C1-C15)-alkyl, (C3-C10)-carbocyclic group or phenyl being each of them can be substituted optionally with one or some similar or different substitutes designated by the formula R5; R5 means halogen atom, (C1-C4)-alkyl, amino-, (C1-C3)-alkoxy-group, (C1-C3)-alkoxycarbonyl or -COOH; X means oxygen or sulfur atom. Also, invention relates to a pharmaceutical composition and to a method for treatment and/or prophylaxis of inflammatory diseases.

EFFECT: valuable medicinal properties of compounds and composition.

9 cl, 2 sch, 2 tbl, 29 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new 1-(p-thienylbenzyl)-imidazoles of the formula (I): , wherein indicated residues represent the following values: R(1) means halogen atom, (C1-C4)-alkoxyl, (C1-C8)-alkoxyl wherein one carbon atom can be replaced with heteroatom oxygen atom (O); R(2) means CHO; R(3) means aryl; R(4) means hydrogen halogen atom; X means oxygen atom; Y means oxygen atom or -NH-; R(5) means (C1-C6)-alkyl; R(6) means (C1-C5)-alkyl in their any stereoisomeric forms and their mixtures taken in any ratios, and their physiologically acceptable salts. Compounds are strong agonists of angiotensin-(1-7) receptors and therefore they can be used as a drug for treatment and prophylaxis of arterial hypertension, heart hypertrophy, cardiac insufficiency, coronary diseases such as stenocardia, heart infarction, vascular restenosis after angioplasty, cardiomyopathy, endothelial dysfunction or endothelial injures, for example, as result of atherosclerosis processes, or in diabetes mellitus, and arterial and venous thrombosis also. Invention describes a pharmaceutical composition based on above said compounds and a method for their applying also.

EFFECT: valuable medicinal properties of compounds and composition.

10 cl, 19 ex

FIELD: medicine, pharmacology, pharmacy, medicinal biochemistry.

SUBSTANCE: invention proposes a pharmaceutical composition that comprises, in particular, N-(1-octyl-5-carboxymethyl-dimethylindolin-7-yl)-2,2-dimethylpropaneamid or its pharmacologically acceptable salts as inhibitor of enzyme ACAT and inhibitor of HMG-CoA-reductase that represents pravastatin, lovastatin, simvaststin, fluvastatin, rivastatin, atorvastatin, rosuvastatin or pitavastatin used as active component of the composition. The combination of active substances shows the expressed synergistic effect. Invention provides enhancing activity of the composition in clinical applying.

EFFECT: valuable medicinal properties of composition.

71 cl, 2 tbl, 3 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to a group of new derivatives of 4,5-dihydro-1H-pyrazole of the general formula (I):

wherein R means phenyl, thienyl or pyridyl and these indicated groups can be substituted with (C1-C3)-alkoxy-group or halogen atom; R1 means phenyl that can be substituted with (C1-C3)-alkoxy-group or pyridyl group; R2 means hydrogen atom or hydroxy-group; Aa means one group among the following groups: (i) , (ii) , (iii) , (iv) or (v) ; R4 and R5 mean independently from one another hydrogen atom or (C1-C8)-branched or unbranched alkyl; or R4 means acetamido- or dimethylamino-group or 2,2,2-trifluoroethyl, or phenyl, or pyridyl under condition that R5 means hydrogen atom; R6 means hydrogen atom at (C1-C3)-unbranched alkyl; Bb means sulfonyl or carbonyl; R3 means benzyl, phenyl or pyridyl that can be substituted with 1, 2 or 3 substitutes Y that can be similar or different and taken among the group including (C1-C3)-alkyl or (C1-C3)-alkoxy-group, halogen atom, trifluoromethyl; or R3 means naphthyl, and its racemates, mixtures of diastereomers and individual stereoisomers and as well as E-isomers, Z-isomers and mixture of E/Z-compounds of the formula (I) wherein A has values (i) or (ii), and its salt. These compounds are power antagonists of Cannbis-1 (CB1) receptor and can be used for treatment of psychiatric and neurological diseases. Except for, invention relates to a pharmaceutical composition used for treatment of some diseases mediated by CB1-receptor, to a method for preparing this composition, a method for preparing representatives of compounds of the formula (I) wherein Aa means group of the formulae (i) or (ii), intermediate compounds used for preparing compounds of the formula (I) and to a method for treatment of some diseases mediated by CB1-receptor.

EFFECT: valuable medicinal properties of compounds.

16 cl, 9 ex

FIELD: medicine.

SUBSTANCE: method involves administering Noliprelum in postoperative period for reducing left ventricle hypertrophy.

EFFECT: enhanced effectiveness of treatment in early postoperative period.

FIELD: organic chemistry, chemical technology, medicine.

SUBSTANCE: invention relates to synthesis of new biologically active substance, namely, to γ-hydroxypropylammonium-5-hydroxynicotinate of the formula (I): , eliciting an anti-ischemic, anti-arrhythmic and hypolipidemic activity. This compound shows low toxicity and absence of cardiodepressive effect. Compound of the formula (I) is prepared by interaction of 5-hydroxynicotinic acid with 3-amino-1-propanol in the presence of a solvent at heating.

EFFECT: valuable medicinal properties of compound.

1 cl, 7 tbl, 3 ex

FIELD: medicine, cardiology.

SUBSTANCE: traditional therapy of myocardial infarction should be supplemented with granocyte introduced either subcutaneously or intravenously at the dosage of 0.48 mln IU/kg body weight daily for 5 d.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: medicine, cardiology.

SUBSTANCE: patient with stenocardia should be introduced with efficient quantity of omapathrylate or its pharmaceutically acceptable salt either separately or in combination with another pharmaceutically active agent. Another pharmaceutically active substance could be represented by organic nitrate, beta-adrenergistic blocking agent, blocking agent of calcium supply or antithrombocytic preparation. It is suggested to apply omapathrylate or its pharmaceutically acceptable salt to prepare medicinal preparations for treating and/or decreasing stenocardial symptoms.

EFFECT: higher efficiency.

16 cl, 2 dwg, 2 ex, 8 tbl

FIELD: medicine, surgery, transplantology.

SUBSTANCE: embryonic spleen should be sampled, washed in nutritive medium № 199 to be placed into fresh medium № 199 to obtain homogenate in teflon homogenizer followed by centrifuging; then one should isolate the upper, medium and inferior layers, suck off medium layer and the upper part of inferior layer; the cell mixture obtained should be diluted in nutritive medium № 199 to be then introduced by injections into mesentery of small intestine or rectus muscle of abdomen. The present innovation favors the activation of immune system in patients undergone splenectomic operation and in those in case of surgical immunodefficient state due to high functional and regenerating activity of transferred embryonic splenic cells.

EFFECT: higher efficiency of prophylaxis.

6 dwg, 2 tbl

The invention relates to medicine, namely to psychiatry and pharmacotherapy of borderline mental disorders
The invention relates to the technology of obtaining biologically active compounds to increase the resistance of the organism of animals

The invention relates to medicine, namely to methods of producing biologically active preparations from bone marrow of animals

The invention relates to medicine, namely to Oncology, and can be used for the treatment of patients with malignant tumors of the organs of the oral cavity and pharynx
The invention relates to medicine, and is intended for the treatment of peritonitis

The invention relates to medicine, namely to Oncology, and can be used to treat cancer of the larynx

The invention relates to medicine, namely to Oncology, and can be used in cancer chemotherapy breast cancer stage III-IV
The invention relates to medicine, namely to traumatology and orthopedics, and can be applied to accelerate the fusion of the bone fragments

FIELD: medicine, surgery, transplantology.

SUBSTANCE: embryonic spleen should be sampled, washed in nutritive medium № 199 to be placed into fresh medium № 199 to obtain homogenate in teflon homogenizer followed by centrifuging; then one should isolate the upper, medium and inferior layers, suck off medium layer and the upper part of inferior layer; the cell mixture obtained should be diluted in nutritive medium № 199 to be then introduced by injections into mesentery of small intestine or rectus muscle of abdomen. The present innovation favors the activation of immune system in patients undergone splenectomic operation and in those in case of surgical immunodefficient state due to high functional and regenerating activity of transferred embryonic splenic cells.

EFFECT: higher efficiency of prophylaxis.

6 dwg, 2 tbl

Up!